IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Abstract Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltrati...

Full description

Bibliographic Details
Main Authors: Nengzhi Pang, Jingxuan Shi, Le Qin, Aiming Chen, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng, Xiaodie Ye, Xiaopei Chen, Lu Wang, Yu Tian, Hao Li, Junping Li, Hong Hu, Jingping He, Yuling Hu, Cheng Zhi, Zhaoyang Tang, Yibo Gong, Fangting Xu, Linfeng Xu, Weijun Fan, Ming Zhao, Deji Chen, Hui Lian, Lili Yang, Peng Li, Zhenfeng Zhang
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Hematology & Oncology
Subjects:
CAR-T cell
IL-7
CCL19
Glypican-3
Mesothelin
Pancreatic carcinoma
Online Access:https://doi.org/10.1186/s13045-021-01128-9

Internet

https://doi.org/10.1186/s13045-021-01128-9

Similar Items